LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Haptoglobin Expression Linked to Newborn Outcomes

By LabMedica International staff writers
Posted on 09 Apr 2019
Print article
Image: Human IL-6 Luminex Performance ELISA Assay (Photo courtesy of R&D Systems).
Image: Human IL-6 Luminex Performance ELISA Assay (Photo courtesy of R&D Systems).
Proteomics has facilitated discovery of biomarkers to better understand the pathophysiology of early-onset neonatal sepsis with the goal of identifying as early as possible the newborns more likely to die or develop significant morbidity.

Some preterm babies born without haptoglobin (Hp), a protein in blood cells, have higher odds of brain bleeding, cerebral palsy and death. This finding suggests that the absence of the protein could serve as a potential biomarker indicating a need for increased monitoring or other preventive interventions.

A large team of scientists working with the University of Illinois at Chicago (Chicago, IL, USA) evaluated cord blood samples from 921 newborns of women at imminent risk for preterm delivery randomized to either placebo (n = 471, birth gestational age (GA) median [min-max]: 31 [24–41] weeks) or magnesium sulphate (n = 450, GA 31 [24–42] weeks]). Primary outcome was infant death by 1 year and/or cerebral palsy (CP) ≥ 2 years of corrected age. Adjusted odd ratios (aOR) for neonatal and childhood outcomes were calculated controlling for GA, birth weight, sex, and magnesium exposure.

The team measured cord blood Hp and interleukin-6 (IL-6) concentrations in all samples. IL-6 was measured with commercial ELISA assays of low and high sensitivity. A cut-off in cord blood Hp immunoreactivity of 3,370 ng/mL in an enzyme-linked immunosorbent assay (ELISA) assay had ~ 100% sensitivity and specificity to segregate samples with switch-off from those with switch-on pattern on Western blots. Because the limit of detection for clinical assays to detect anhaptoglobinemia in adults is 2 mg/dL, Western blots were performed on all cord blood samples measuring Hp ≥ 2,000 ng/mL by ELISA (n = 507). Analysis of the magnesium concentration in cord serum was performed with a minimum detectable magnesium concentration of 0.4 mEq/L.

The scientists reported that primary outcome occurred in 2.8% of offspring. Newborns were classified in three pre-defined categorization groups by cord blood Hp switch status and IL-6 levels: inflammation-nonexposed (n = 432, 47%); inflammation-exposed haptoglobinemic (n = 449, 49%), and inflammation-exposed anhaptoglobinemic or hypohaptoglobinemic (n = 40, 4%). Newborns, found anhaptoglobinemic or hypohaptoglobinemic had increased OR for intraventricular hemorrhage (IVH) and/or death (aOR: 7.0) and for CP and/or death (aOR: 6.27) compared with Category 2. Fetal ability to respond to inflammation by haptoglobinemia resulted in aOR similar to inflammation-nonexposed newborns. Hp1-2 or Hp2-2 phenotypes protected against retinopathy of prematurity (aOR = 0.66).

The authors concluded that fetal ability to switch-on Hp expression in response to inflammation was associated with reduction of IVH and/or death, and CP and/or death. Fetuses unable to mount such a response had an increased risk of adverse outcomes. Catalin S. Buhimschi MD, a professor of obstetrics and gynecology the lead author of the study said, “Our study provides strong evidence that an absence of haptoglobin in preterm babies who have been exposed to inflammation is an indicator of increased risk for complications like brain bleeding, cerebral palsy and even death. This underscores the potential protective role of haptoglobin against short- and long-term poor neonatal outcomes and suggests that the protein may be a valuable marker of neurologic damage and the need for clinical interventions.” The study was published on March 22, 2019, in the journal EClinicalMedicine.

Related Links:
University of Illinois at Chicago

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.